MINERVA NEUROSCIENCES INC (NERV)
US6033802058 - Common Stock
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...
Minerva stock falls as FDA rejects schizophrenia drug
Minerva Neurosciences (NERV) stock falls as the FDA rejects its schizophrenia drug candidate, roluperidone. Read more here.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Company to host conference call today at 8:30 a.m. ET
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Company to host conference call today at 8:30 a.m. ET...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug...